Ranger Investment Management L.P. Invests $6.74 Million in BioLife Solutions, Inc. $BLFS

Ranger Investment Management L.P. bought a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in the second quarter, Holdings Channel reports. The institutional investor bought 238,521 shares of the medical equipment provider’s stock, valued at approximately $6,736,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. bought a new stake in BioLife Solutions in the first quarter worth $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in BioLife Solutions by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock valued at $489,000 after purchasing an additional 914 shares in the last quarter. Jane Street Group LLC bought a new position in BioLife Solutions during the first quarter valued at $1,091,000. Strs Ohio bought a new position in BioLife Solutions during the first quarter valued at $153,000. Finally, Qube Research & Technologies Ltd grew its stake in shares of BioLife Solutions by 2,399.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock worth $5,352,000 after buying an additional 238,533 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $37.10 on Monday. The company has a fifty day moving average of $30.34 and a two-hundred day moving average of $24.88. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 31.98 and a beta of 1.93. BioLife Solutions, Inc. has a 52 week low of $17.86 and a 52 week high of $38.10.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.88. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. The business had revenue of $28.47 million for the quarter, compared to analysts’ expectations of $27.80 million. Equities research analysts anticipate that BioLife Solutions, Inc. will post 0.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BLFS. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Friday, July 17th. Stephens reaffirmed an “equal weight” rating and issued a $31.00 price target (down from $32.00) on shares of BioLife Solutions in a report on Monday, July 27th. Jefferies Financial Group lowered BioLife Solutions from a “buy” rating to a “hold” rating and lifted their price target for the stock from $30.00 to $31.00 in a research report on Thursday, July 23rd. William Blair set a $31.00 price objective on BioLife Solutions in a research note on Thursday, July 23rd. Finally, Maxim Group downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions presently has an average rating of “Hold” and an average target price of $31.38.

BioLife Solutions Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.